Video

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

Author(s):

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

Chau T. Dang, MD, the Regional Care Network Medical Site Director at Memorial Sloan Kettering Westchester, discusses the safety profile of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. 

The 5-year results from the final analysis of the phase 2 BERENICE trial (NCT02132949), which were presented during the ESMO Breast Cancer Virtual Meeting 2021, showed that in cohort A of the study, in which patients were treated with standard anthracycline-based chemotherapy followed by pertuzumab/trastuzumab and paclitaxel, incidence of New York Heart Association (NYHA) class III/IV heart failure was 1.5% in the neoadjuvant setting, Dang says.

Additionally, in cohort B, where patients received treatment with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel and pertuzumab/trastuzumab, no incidence of NYHA class III/IV heart failure was reported, Dang notes. 

The study followed patients through to the treatment-free follow-up period to report events after the neoadjuvant setting, Dang explains. For cohort A, no additional cardiac events were reported after the neoadjuvant phase, keeping the rate of NYHA class III/IV heart failure at 1.5%. In cohort B, 1 cardiac event was reported in the adjuvant setting, and 1 during the treatment-free follow-up period, which brought the NYHA class III/IV heart failure rate to 1%, Dang concludes. 

Related Videos
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marc Machaalani, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD